BRCA2 (BRCA2) ELISA试剂盒产品概述

Full name:
Breast Cancer 2, Early Onset ELISA试剂盒 (BRCA2)
在www.antibodies-online.cn可供24 Breast Cancer 2, Early Onset (BRCA2) ELISA试剂盒的7不同的供货商。 再加上,我们可以发BRCA2 抗体 (89)BRCA2 蛋白 (2)和数多这个蛋白质的别的产品。 总共118 BRCA2产品已列进来了。
别名:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
list all ELISA KIts 基因 基因ID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

显示所有的来源

显示所有的同义词

适于 BRCA2 相互作用对的更多 ELISA 试剂盒

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (显示 TP53 ELISA试剂盒) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  2. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (显示 PALB2 ELISA试剂盒) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (显示 PALB2 ELISA试剂盒) and Trp53 (显示 TP53 ELISA试剂盒) heterozygosity .

  3. Merit40 (显示 BABAM1 ELISA试剂盒) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (显示 FANCD2 ELISA试剂盒) mutation.

  4. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  5. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  6. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (显示 PARP1 ELISA试剂盒) inhibition.

  7. BRCA2-mediated sequestration of nuclear RAD51 (显示 RAD51 ELISA试剂盒) serves to prevent inappropriate DNA interactions.

  8. BRCA2 directly represses the expression of IFN-related genes

  9. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  10. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. These results reveal a synthetic lethal relationship between FANCD2 and BRCA1/2.

  2. This study implicates novel risk loci as well as highlights the clinical utility for retesting BRCA1/2 negative ovarian cancer patients by genomic sequencing and analysis of genes in relevant pathways.

  3. Women with BRCA1/2 mutations show at diagnosis higher peritoneal tumor load and increased frequency of bulky lymph nodes compared to patients without germline BRCA mutations. Primary debulking surgery seems to ensure a longer progression-free survival in women with BRCA wild type genotype compared to neoadjuvant chemotherapy.

  4. Sixteen VUS from 51 BRCA1 variants of uncertain significance (VUS) carriers and 28 VUS from 62 BRCA2 VUS carriers were analyzed. There was a slight agreement between the two analyses, with a kappa value of 0.14 (95% confidence interval (CI) = -0.34 to 0.62) for the BRCA1 VUS and a kappa value of 0.17 (95% CI = -0.10 to 0.49) for the BRCA2 VUS

  5. Study showed that the prevalence of BRCA1/2 germline mutations was 19% in epithelial ovarian cancer, mostly detected in different gene locations. Two novel frameshift mutations were identified, one in BRCA1 and one in BRCA2, as well as two large deletions.

  6. Architectural plasticity of human BRCA2-RPA (显示 RPA1 ELISA试剂盒)-RAD51 (显示 RAD51 ELISA试剂盒) complexes in DNA break repair has been described.

  7. This study shows that BRCA mutation carriers could be frequently identified among breast cancer patients with multiple risk factors. Importantly, we established an NGS-based pipeline for BRCA1/2 testing in clinical practice and strongly suggest that breast cancer patients of premier- and moderate-grade risks receive BRCA1/2 mutations testing in China

  8. Studies suggest that people with high risk of breast cancer and negative BRCA1/BRCA2 should be tested for PALB2 (显示 PALB2 ELISA试剂盒) mutations.

  9. These findings suggest that R2787H variant of BRCA2 could have potential functional impact.

  10. Even if a BRCA2 mutation is already identified within a family, the presence of early onset breast cancer affected non-carriers hampers accurate risk estimates for both mutation carriers and other negative family members.

BRCA2 抗原简介

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) Elisa Kit
  • breast cancer 2, early onset (brca2) Elisa Kit
  • breast cancer 2 (Brca2) Elisa Kit
  • breast cancer 2, early onset (Brca2) Elisa Kit
  • AI256696 Elisa Kit
  • AW045498 Elisa Kit
  • BRCA2 Elisa Kit
  • BRCC2 Elisa Kit
  • BROVCA2 Elisa Kit
  • FACD Elisa Kit
  • FAD Elisa Kit
  • FAD1 Elisa Kit
  • FANCB Elisa Kit
  • FANCD Elisa Kit
  • FANCD1 Elisa Kit
  • GLM3 Elisa Kit
  • PNCA2 Elisa Kit
  • RAB163 Elisa Kit

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
BRCA2 (BRCA2) ELISA试剂盒 精选生产商
您还需要查找其他产品吗?